GlassScriptPhysician profile
Andrew T Cheung
NPI 1164658662
$6,441.29
in general payments reported to CMS, 2019-2025
30 companies · $866 in 2025
The $866 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $194 · 2021: $403 · 2022: $1,348 · 2023: $1,600 · 2024: $1,394 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,846.45 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,420.47 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $800.40 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $578.18 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $428.89 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $320.42 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $320.38 | 2019-2024 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $295.42 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $274.95 | 2022-2025 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $259.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $234.43 | 2024-2025 | |
| Travere Therapeutics, INC. | $192.63 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $151.86 | 2022-2023 | Acthar |
| Baxter Healthcare | $125.00 | 2022 | |
| Fresenius USA Marketing, INC. | $117.18 | 2022-2024 | Velphoro |
| Abbvie INC. | $115.68 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $101.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.90 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $86.63 | 2019-2022 | |
| Lilly USA, LLC | $84.25 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $78.66 | 2024-2025 | Ultomiris |
| Daiichi Sankyo INC. | $71.91 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $68.25 | 2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $44.78 | 2024 | Ibsrela |
| Veloxis Pharmaceuticals, INC. | $34.98 | 2025 | Envarsus |
| Amicus Therapeutics, INC. | $31.29 | 2022 | |
| Bard Peripheral Vascular, INC. | $27.91 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $27.11 | 2022 | |
| Kyowa Kirin, INC. | $22.06 | 2025 | |
| Scpharmaceuticals INC. | $17.96 | 2025 | |
| Opko Pharmaceuticals, LLC | $16.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.